이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Yifan Pharmaceutical 관리

관리 기준 확인 4/4

Yifan Pharmaceutical's CEO는 Xian Feng Cheng, Nov2017 에 임명되었습니다 의 임기는 6.58 년입니다. 는 CN¥ 6.32B 가치에 해당하는 회사 주식의 40.82% 직접 소유합니다. 6.32B. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 8.9 년입니다.

주요 정보

Xian Feng Cheng

최고 경영자

CN¥624.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	6.8yrs
CEO 소유권	40.8%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	9.2yrs

최근 관리 업데이트

Recent updates

CEO

Xian Feng Cheng (56 yo)

6.8yrs

테뉴어

CN¥624,000

보상

Mr. Xian feng Cheng serves as the Chairman of the Board of Directors at Yifan Pharmaceutical Co., Ltd and serves as its Director since October 15, 2014 and serves as its General Manager since November 07,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Xian Feng Cheng	Chairman of the Board of Directors & GM	6.8yrs	CN¥624.00k	40.82% CN¥ 5.8b
Dawei Zhang	Financial Director	1.2yrs	CN¥240.00k	0.0032% CN¥ 448.1k
Xing Lin	Deputy GM & Director	11.8yrs	CN¥564.00k	0.063% CN¥ 8.9m
Deqi Feng	Board Secretary	no data	CN¥480.00k	0.060% CN¥ 8.5m
Ximing Li	Deputy General Manager	2.3yrs	CN¥2.74m	0.0020% CN¥ 284.1k
Yuhong Geng	Deputy General Manager	2.3yrs	CN¥1.87m	0.0032% CN¥ 453.7k
Kai Wang	Head of Accounting	no data	데이터 없음	데이터 없음
William Tan	Director of Sales Team	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 관리: 002019 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xian Feng Cheng	Chairman of the Board of Directors & GM	9.9yrs	CN¥624.00k	40.82% CN¥ 5.8b
Xing Lin	Deputy GM & Director	11.8yrs	CN¥564.00k	0.063% CN¥ 8.9m
Deqi Feng	Board Secretary	8.4yrs	CN¥480.00k	0.060% CN¥ 8.5m
Jun Wang	Supervisor	6.5yrs	데이터 없음	0.000010% CN¥ 1.4k
Lian Chun Zhang	Member of the Supervisory Board	9.9yrs	CN¥234.20k	데이터 없음
Yi Qun Ye	Director	9.9yrs	CN¥480.00k	0.058% CN¥ 8.2m
Ben Yu Zhou	Director	9.9yrs	CN¥480.00k	0.032% CN¥ 4.6m
Hongquan Liu	Independent Director	3.8yrs	CN¥100.00k	데이터 없음
Xintu Lei	Independent Director	5.4yrs	CN¥100.00k	데이터 없음
Hong Cheng Gen	Independent Director	5.4yrs	CN¥100.00k	데이터 없음

9.2yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: 002019 의 이사회는 경험(평균 재직 기간 8.9 년)으로 간주됩니다.

Yifan Pharmaceutical 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Recent updates

New major risk - Dividend sustainability

Yifan Pharmaceutical Co., Ltd. Proposes Interim Dividend for the First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.039 in 2Q 2023)

Yifan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.45 loss per share (vs CN¥0.16 profit in FY 2022)

Yifan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.032 in 3Q 2022)

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.031 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.23 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.069 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.031 (vs CN¥0.062 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 1Q 2021)

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings released: EPS: CN¥0.23 (vs CN¥0.80 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.16 in 3Q 2020)

Investor sentiment improved over the past week

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 150 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.32 in 2Q 2020)

Yifan Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan A Shares for 2020, Payable on 17 May 2021

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.80 (vs CN¥0.75 in FY 2019)

Investor sentiment improved over the past week

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥16.91

New 90-day low: CN¥18.19

New 90-day low: CN¥20.47

New 90-day low: CN¥22.10

Third quarter earnings released

New 90-day low: CN¥23.93

First half earnings released

Yifan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

New 90-day high - CN¥32.91

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령